



Press Release

MSN Group is all set to launch MOLULOW 200 mg capsules, generic of molnupiravir, for treatment of Covid-19 in India.

Hyderabad, 6th January 2022: MSN Group, one of the fastest-growing, research-based and fully integrated pharmaceutical companies based out of Hyderabad, India is all set to launch the generic **molnupiravir 200 mg capsules** for treating COVID-19 under the brand name **MOLULOW**.

Molnupiravir is an oral COVID-19 antiviral medicine indicated for the treatment of mild-to-moderate COVID-19 in adults with a positive SARS-CoV-2 diagnostic test and who have at least one risk factor for developing severe illness.

MSN Group Commented: “After enabling affordable access to a series of critical Covid-19 drugs like Oselow, Favilow, Baridoz, and Posaone etc., at crucial junctures, we at MSN Group are glad to be launching **MOLULOW**, which can be a game-changer in our nation’s fight against the pandemic. Being an orally administered option, we are confident that this medicine will increase treatment compliance and bring relief to the Covid-19 patients.”

MOLULOW, which received Emergency Use Approval (EUA) approval from DCGI, comes as a pack of 4x10 capsule strips with each capsule in 200 mg strength. A dosing regimen of 800 mg (BID) for five days (four capsules of 200 mg twice a day) is recommended in addition to standard medical care. **MOLULOW** is being manufactured at MSN Group’s USFDA & MHRA accredited facility based out of Hyderabad. The drug, to be dispensed upon a medical prescription, will be made available at all retail pharmacies soon at the most affordable price.

MSN Group, which has successfully conducted clinical trials of molnupiravir in India and presented its findings to DCGI, has recently received the licence from the Medicines Patent Pool (MPP) for manufacturing and distribution of MSD’s [MSD (NYSE: MRK), a trade name of Merck & Co., Inc, Kenilworth, NJ, USA.] molnupiravir for treating Covid-19. This agreement will also help MSN Group in enabling access to molnupiravir in over 100 low- and middle-income countries (LMICs) following regulatory approvals of respective countries.

For more information on MOLULOW, please reach out to customercare@msnlabs.com

**About MSN Group:**

MSN Group is one of the fastest-growing, research-based and fully integrated pharmaceutical companies based out of Hyderabad, India. It was founded in the year 2003 with a mission to make high-quality medicines affordable and accessible to the world. The organization presently has 16 state-of-the-art manufacturing facilities (twelve API and four finished dosage facilities) established across India and USA. The Group has an integrated R&D center for both API and formulation under one roof, dedicated to research and development of pharmaceuticals. With its core focus on speed and consistency in delivery, MSN has more than 823 national and international patents filed, over 130 ANDAs, and emerged as world no. 1 in active US DMF filings. The company, with a product portfolio of 450+ APIs and 300+ formulations spanning 35 major therapies, has won the trust of more than 40 million patients in 65 countries across the world.

For information on MSN Labs, please visit www.msnlabs.com

MSN Labs Media Contact:

PVR Surya Kanth

Corporate Communications

Mobile: +91 8790829841

E-mail: pvr.suryakanth@msnlabs.com